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The neuropathic pain special interest group (NeuPSIG) of the International Association 
for the Study of Pain has proposed a grading system for the presence of neuropathic pain 
(NeP) using the following categories: no NeP, possible, probable or definite NeP. To 
further evaluate this system we investigated patients with neck/upper limb pain with a 
suspected nerve lesion, to explore: (i) the clinical application of this grading system; (ii) 
the suitability of two NeP questionnaires (Leeds Assessment of Neuropathic Symptoms 
and Signs pain scale (LANSS); painDETECT questionnaire (PD-Q)) in identifying NeP 
in this patient cohort and; (iii) the level of agreement in identifying NeP between the 
NeuPSIG classification system and two NeP questionnaires. Patients (N=152; age 52 ± 
12 years; 53% male) completed the PD-Q and LANSS questionnaire and underwent a 
comprehensive clinical examination. The NeuPSIG grading system proved feasible for 
application in this patient cohort, although required considerable time and expertise. Both 
questionnaires failed to identify a large number of patients with clinically-classified 
definite NeP (LANSS sensitivity 22%, specificity 88%; PD-Q sensitivity 64%, specificity 
62%). These lowered sensitivity scores contrast with those from the original PD-Q and 
LANSS validation studies and may reflect differences in the clinical characteristics of the 
study populations. The diagnostic accuracy of LANSS and PD-Q for the identification of 




Neuropathic pain (NeP), defined as “pain arising as a direct consequence of a lesion 
or disease affecting the somatosensory system” [42;64] is associated with more severe 
pain for patients than nociceptive pain [18;30] and with suffering, disability, impaired 
health-related quality of life [13;25;30], and increased health care cost [30;60]. Thus, 
early identification of NeP is crucial, as NeP in particular requires targeted 
management [4;38]. As no “gold standard” exists for the diagnosis of NeP, a grading 
system with different levels of certainty about the presence of NeP (no, possible, 
probable, definite) has been developed by the Neuropathic Pain Special Interest 
Group (NeuPSIG) of the International Association for the Study of Pain [64]. This 
classification approach is based on a stepwise process that requires a history-derived 
working hypothesis (based on pain distribution and history suggesting a relevant 
lesion), and confirmatory evidence from a neurological examination and diagnostic 
tests. The application of this grading system has been demonstrated in some case 
studies [31;35], and was consequently used in various pain populations [32;39;43], 
but not in patients with neck/upper limb pain. 
 
Questionnaires are used as screening tools to aid identification of suspected NeP 
[10;22] and are recommended for clinical use, including by non-specialists [34]. The 
Leeds Assessment of Neuropathic Symptoms and Signs pain scale (LANSS)[9] 
discriminates between patients with or without pain of predominantly neuropathic 
origin, and is applied in an interview format. The LANSS contains five sensory 
descriptor items and two clinical examination items. LANSS was developed in 60 
patients with distinct clinical diagnostic categories of NeP and non-NeP, and 
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demonstrated a sensitivity of 83% and specificity of 87%, and was further validated in 
40 patients (sensitivity 85%, specificity of 80%) [9]. 
 
The painDETECT questionnaire (PD-Q) [30] is another NeP screening tool, with the 
additional concept of grading for the certainty of the presence of NeP. PD-Q classifies 
patients into three groups: a NeP component is unlikely, results are ambiguous, or a 
NeP component is likely. The questionnaire is a self–administered tool consisting of 
seven weighted sensory descriptors, plus one item relating to spatial pain 
characteristics and one relating to temporal characteristics. PD-Q was developed and 
validated in 392 German patients with clinically diagnosed pain of predominantly 
either nociceptive or neuropathic origin and demonstrated a sensitivity of 85% and 
specificity of 80%.  
 
LANSS and PD-Q appear to demonstrate the same level of diagnostic accuracy in 
identifying NeP. However, it is unclear if they have similar performances when 
applied to a single patient cohort presenting with mixed musculoskeletal and 
peripheral NeP. If this were the case, the use of PD-Q would be preferable in primary 
care, as it would save valuable practitioner time. 
 
The aims of this study were to investigate:  
(i) the clinical application of the NeuPSIG grading system in patients with 
neck/upper limb pain; 
(ii) the suitability of LANSS and PD-Q as tools for the accurate identification 
of NeP in these patients 
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(iii) the level of agreement in detecting NeP between the NeuPSIG 
classification system and the LANSS and PD-Q.  
 
 8 
2. Materials and methods 
2.1. Study population 
The study (prospective) was conducted between June 2008 and December 2009 
inclusive. Patients with neck/upper limb pain and suspected nerve lesion were 
recruited from an outpatient neurosurgery triage clinic in a large metropolitan 
hospital. Patients had been referred to this clinic by their general practitioner or from 
other departments within the hospital. The study was registered with the Quality 
Improvement Unit of Sir Charles Gairdner Hospital (registration number 2109) and 
endorsed by the Hospital’s Human Research Ethics Committee.  
 
2.2.Clinical examination 
All study patients were examined by a clinician with a postgraduate Masters 
qualification in musculoskeletal physiotherapy and who specialised in triaging 
patients with musculoskeletal and neuropathic pain disorders in a tertiary 
neurosurgical setting (BT). The clinician was not blinded to the patient referral, 
however a referral may not have contained a diagnosis as often the patient’s 
symptoms rather than a diagnosis were described, i.e. neck pain with tingling in the 
hand. The clinical assessment comprised of taking the patient’s history, pain drawings 
including location and intensity of pain, documentation of pain descriptors and pain 
behaviours, musculoskeletal assessments and neurological examination. Sensory 
testing of light touch and pin-prick sensation was performed in the most painful area 
[34] and compared with findings in the contralateral corresponding control site. In 
patients with bilateral pain, proximal or distal pain-free sites were used for control 
testing [34;35;41]. Thermal testing was not performed in this study, consistent with 
previously documented methodology [9;17;39;66]. Pin-prick thresholds can give 
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comparable information on the function of unmyelinated C-fibers as a strong 
correlation between pin-prick and thermal thresholds has been shown [20]. 
Furthermore it has been commented that the assessment of thermal sensitivity is 
considered less practical due to the requirement for special equipment [17]. Patients 
were asked to report the stimulus intensity (normal, less = hypoaesthesia; more = 
hyperaesthesia) and quality (normal or other = paraesthesia, dysaesthesia, allodynia) 
compared to the control site. Sensory testing was also performed in both upper limbs 
for determination of dermatomal sensory deficits and in both lower limbs, if spinal 
cord compromise was suspected. Finally, available results from any other 
investigations (i.e. imaging, nerve conduction studies (NCS)) were reviewed to 
identify any evidence of a lesion/disease of the somatosensory system. Based on all 
the above findings patients’ pain conditions were categorised by the one clinician 
according to the NeuPSIG classification system, using a hierarchical order, into either 
no NeP, possible, probable or definite NeP. As some patients presented with multiple 
pain areas, the classification for NeP was applied to the patient’s maximal pain area. 
 
The classification system comprises the following four criteria [64]: 
1. Pain with a distinct neuroanatomically plausible distribution 
2. A history suggestive of a relevant lesion or disease affecting the peripheral or 
central somatosensory system 
3. Demonstration of the distinct neuroanatomically plausible distribution by at 
least one confirmatory test (presence of negative or positive sensory signs 
concordant with the distribution of pain) 
4. Demonstration of the relevant lesion or disease by at least one confirmatory 
test (e.g. neuroimaging, neurophysiological methods) 
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Definite NeP is defined by the presence of all 4 criteria; probable NeP is defined by 
the presence of Criteria 1 and 2, plus either 3 or 4 and possible NeP by the presence of 
Criteria 1 and 2, without confirmatory evidence from 3 or 4 [64]. With respect to 
Criterion 3, in our study only sensory abnormalities in the main pain area were 
classified as a confirmatory response. If no abnormalities were found in the main pain 
area, but sensory changes existed in further distal areas (e.g. distal dermatomal 
sensory changes in patients with cervical radiculopathy), this was classified as not 
fulfilling Criterion 3. If imaging results were used for radiological confirmation of 
nerve compression, only radiologist’s reports indicating significant/severe cervical 
foraminal stenosis and compromise of the exiting nerve root at the clinically relevant 
level were deemed as a confirmatory test. If the report stated “mild to moderate 
foraminal narrowing” with no mention of nerve root compromise, this was classified 
as a non-confirmatory test. The radiologist’s grading of nerve root compromise was 
based on standard radiology reporting procedures as defined by an experienced 
neuroradiologist. 
 
While some studies used the consensus of two clinicians for validation of patient 
classification, others have used only a single clinical judgement [9;11;24;36;39;66]. 
Our approach is consistent with the latter and was chosen as we encountered the 
problem of time and resource limitations required for patient assessment by two 
examiners. Furthermore, repeated assessment would have imposed a considerable 
burden on the patients and could potentially cause an exacerbation of the patients’ 






The LANSS was chosen for this project as it has been documented in several studies 
to be a reliable and valid tool for the identification of NeP [9;54;65;68], including the 
identification of NeP in patients with cervical or lumbar radiculopathy [9;54;65;68]. 
The PD-Q is a much more recent tool, is easy to implement in clinical practice, is 
available in English and has been applied in English speaking populations [7;29;33]. 
In contrast to all other NeP screening tools [10], PD-Q was designed for identifying 
NeP components specifically in low back pain patients with and without referred pain. 
The PD-Q as well as LANSS might be transferable to neck pain conditions with and 
without referred pain and therefore seemed appropriate to be used for our patient 
cohort. 
 
All participants completed the PD-Q prior to clinical examination whilst they were in 
the waiting room. No specific instructions were given to patients on how to complete 
the questionnaire, consistent with the PD-Q format. The questionnaire asks patients to 
mark their main pain area on a body chart. The weighted sensory item descriptors 
relate to this marked main pain area. A PD-Q score of ≤ 12 indicates that a NeP 
component is unlikely, and a score of ≥ 19 indicates a likely presence of a NeP 
component [30]. Scores between 13 and 18 reflect an ambiguous result. The clinician 
was blinded to the PD-Q responses. The LANSS was administered unblinded in an 
interview format at the end of the clinical examination. The required testing for the 
LANSS (testing for allodynia with cotton wool, altered pin-prick threshold with 23 
gauge needle) was performed during the overall neurological bedside examination. A 
score of < 12 indicates that neuropathic components are unlikely to contribute to the 
patient’s pain and a score of ≥ 12 suggests that NeP components are likely to be 
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contributing to the pain presentation. In addition, the strongest and average pain 
intensity over the last four weeks and pain intensity at the time of the assessment were 





2.4. Statistical analysis 
Data were analysed using the Statistical Package for Social Sciences (SPSS Version 
17.0). One-way ANOVA and Kruskal-Wallis test were used to compare patient 
characteristics between pain classification groups (no, possible, probable, and definite 
NeP). Frequencies of pain descriptors were calculated. A pair-wise comparison was 
performed between:  
• clinical classification and LANSS;  
• clinical classification and PD-Q; 
• LANSS and PD-Q.  
The Kappa coefficient and 95% confidence intervals were calculated for all 
comparisons as well as the percentage of agreement [46]. As the LANSS uses a 
dichotomous scale, PD-Q and the clinical classification score were transformed into 
dichotomous variables: PD-Q scores < 19 were defined as no NeP and ≥ 19 as NeP. 
For the clinical classification, no, possible and probable NeP were all grouped as no 
NeP. Sensitivity and specificity were calculated for the LANSS and PD-Q, using the 
clinical classification as the “gold standard” [56]. Sensitivity was calculated by 
dividing the true positives by the sum of true positives and false negatives [56]. 
Specificity was calculated by dividing the true negatives by the sum of true negatives 
and false positives. Predictive values (positive and negative predictive values, 
likelihood ratios, diagnostic odds ratios) were also calculated. The receiver operating 
characteristic (ROC) curves were graphed and the areas under the curve (AUC) plus 
their 95% confidence intervals were calculated for each questionnaire. The ROC 
curve analysis was used to determine the cut-off score for the questionnaires used. 
Logistic regression analysis was performed to examine the utility of each item 
descriptor of the LANSS and PD-Q to discriminate NeP. For the latter analysis, the 
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seven item descriptors of the PD-Q which have five possible scores (never = 0; hardly 
noticed = 1; slightly = 2; moderately = 3; strongly = 4; very strongly = 5) were 
transformed into dichotomous variables.  Scores ≥ 3 were defined as a positive 
response and scores of < 3 as a negative response, consistent with previous 
methodology [62]. 
 
Furthermore, given the concept of grading the certainty of the presence of NeP in both 
the clinical classification system and PD-Q, an analysis was performed to compare the 
agreement in classifying patients as having NeP, no NeP and unclear/ambiguous 
classification. To investigate whether the questionnaires were able to identify patients 
who were clinically classified as having probable NeP, consistent with other studies 
[32;43;65], three categories per classification were defined as follows: LANSS 
(scores 0 – 8 = no NeP [12], 9 – 11 unclear, 12 – 24 NeP), PD-Q (scores 0 – 12 = no 
NeP, 13 – 18 = unclear, 19 - 38 = NeP) and clinical classification (no NeP, possible as 
unclear cases, and probable and definite combined as NeP). The Kappa coefficient 
and 95% confidence intervals were calculated for all comparisons, as well as the 
percentage of agreement. Other data are presented as mean (SD) unless otherwise 




One hundred and sixty six patients with neck/upper limb pain attended the 
neurosurgery triage clinic, and of these,13 did not experience any pain or only 
paraesthesia at the time of assessment. One patient was excluded from data analysis 
due to errors in completing the PD-Q, so analyses were performed on 152 patients.  
 
3.1. Patient characteristics 
The patients’ characteristics are shown in Table 1. No listed characteristic was 
significantly different between the pain classification groups. Patients more likely to 
have NeP demonstrated a tendency to higher maximal pain scores during the 
preceding 4 weeks. A wide spectrum of pain diagnoses/pain presentations was 
represented (Table 2). Ninety-five patients (62.5%) presented with conditions likely 
to include NeP (radiculopathy, radicular pain, cervical myelopathy and carpal tunnel 
syndrome) and 57 patients (37.5%) with predominantly musculoskeletal/nociceptive 
conditions. Clinical presentations ranged from the presence of a single pain area to 
multiple causally related pain areas (e.g. neck pain with referred or projected arm pain 
and paraesthesia) or multiple independent areas (e.g. neck/arm pain with signs of 
carpal tunnel syndrome). Twenty-four patients experienced bilateral symptoms. Apart 
from the pain presentations shown in Table 2, 24 patients presented with additional 
pain areas, which were independent of their main pain area/main complaint (low back 
pain (LBP) n = 11, LBP with leg pain n = 4, leg pain n = 3, shoulder pain n = 5, wrist 
pain n = 1). Seventy patients had various co-morbidities such as diabetes, thyroid 
dysfunction, hepatitis B and C, heart and lung disease, migraine, irritable bowel 
syndrome, cancer, polymyalgia rheumatica, Parkinson’s disease, transient ischemic 
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attack, gout, fibromyalgia, epilepsy, brain aneurysm and depression and anxiety 
disorders.  
 
3.2. Clinical classification of NeP based on the NeuPSIG system 
The assessment of each patient required on average a 45 minutes consultation. Fifteen 
patients were classified as no NeP, 27 as possible NeP, 65 as probable NeP and 45 as 
definite NeP (Table 2).  
 
Criterion 1 
Fifteen patients were classified as having no NeP as their pain distribution was not in 
a distinct neuroanatomically plausible distribution. 
 
Criterion 2 
Seventy patients with spinal pain could not recall a specific onset of their pain, 
therefore it was not possible to establish an exact temporal link between history and 
pain distribution. An insidious onset is common for the development of pain 
associated with spinal degenerative changes [59] and it was determined that these 
cases therefore satisfied Criterion 2. 
 
Criterion 3 
Sensory abnormalities in the main area of pain were demonstrated in 41 out of the 65 
patients classified as having probable NeP and in all patients with definite NeP. Fifty-
two patients presented with more than one sensory abnormality (no NeP, n = 1; 
possible NeP, n = 0; probable NeP, n = 24; definite NeP, n = 27). Five patients 
demonstrated allodynia. The presence of hyposensitivity to one or several modalities 
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(light touch, pin-prick) (n = 44) was more common than hyperaesthesia (n = 31). Ten 
patients presented with mixed hypo- and hypersensitivities.  
 
Seven patients classified as having probable NeP, and three patients with possible 
NeP, did not have any sensory abnormalities in their main pain area. However, all 
these patients demonstrated sensory deficits in a distal dermatomal distribution, and 
this combined with the clinical history supported the likely presence of a nerve lesion. 
According to our interpretation these cases did not satisfy Criterion 3. In three 
patients with probable NeP, no sensory abnormalities were found in the main area of 
pain, but sensory abnormalities were present in a distal, non-dermatomal distribution, 
and were not causally related to the main area of pain. These cases were also 
interpreted as not fulfilling Criterion 3. For two patients, sensory abnormalities were 
not recorded in the area of maximal pain (neck pain), but in a projected pain area 
(arm), and this was interpreted as a confirmatory test for Criterion 3 [45]. In 24 
patients classified as probable NeP, no sensory abnormalities were found in the main 
pain area or in distal dermatomal areas, but confirmatory tests of nerve compression 
were available to determine the classification of probable NeP (NCS: n = 1; surgery: n 
= 1; Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI): n = 




Imaging results of the cervical spine to allow possible radiological confirmation of 
nerve compression were available for 140 patients (plain radiography n = 7; CT n = 
108; MRI n = 25). Considering the possibility of false positive findings on imaging 
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[47;50], we adopted a very conservative approach and defined only radiologist’s 
reports indicating significant/severe cervical foraminal stenosis and compromise of 
the exiting nerve root at the clinically relevant level as a confirmatory test. Plain 
radiography was not considered as a confirmatory test. Results of NCS were available 
for six patients. Of nine patients without any diagnostic tests, three were classified 
with probable NeP, three with possible and three with no NeP. 
 
3.4. Volunteered pain descriptors 
The frequency of reported pain descriptors obtained during the clinical examination 
from patients classified as having no NeP, possible, probable or definite NeP are 
shown in Figure 1. The description of electric shock type pain occurred only in the 
probable and definite NeP groups. Tingling sensations and the presence of sharp pain 
was most frequently reported in the probable and definite NeP groups (20% -28.9%) 
and not at all in the no NeP group. Other pain descriptors associated with NeP (e.g. 
numb, hot, shooting) were also not used in the no NeP category and occurred 
infrequently in the probable and definite group (4.4% - 12.3%). The descriptors 
burning and ache were reported in all groups in the following proportions: burning 
pain 26.7% in no NeP; 22.2% in possible NeP; 32.3% in probable and 35.6% in 
definite NeP respectively; ache 33.3% in no NeP, 11.1% in possible NeP, 24.6% in 
probable NeP; and 26.7% in definite NeP. Spontaneous pain was reported in 41% of 
patients during the clinical examination with increased frequency and increased 
likelihood of NeP (no NeP, n = 1; possible NeP, n = 10; probable NeP, n = 26; 




3.5. Agreement between clinical classification and questionnaires where patients 
were classified as having NeP or no NeP  
 
3.5.1 LANSS and clinical classification of NeP 
Twenty-three patients met the LANSS criteria for predominantly NeP (mean (SD) 
score 14.3 (2.0)) and 129 for without predominantly NeP (6.0 (3.8)) (Table 3). There 
was agreement between the LANSS and the clinical classification in 104 of the 152 
cases (no NeP: n = 94, NeP: n = 10; Kappa 0.12, 95% CI -.04 to .28) (Table 3), which 
yielded a 68.4% agreement. Using the clinical classification as the “gold standard”, 
LANSS demonstrated a sensitivity of 22% and specificity of 88% (Table 4). The 
ROC curve is presented in Figure 2. The AUC for the LANSS was 0.73 (95% CI .64 
to .81). The appropriate cut-off score for our patient cohort was 8.5. 
 
Out of 48 discordant cases between LANSS and clinical classification, 16 patients 
(33%) scored very close to the original cut off score of ≥ 12 (11 patients scored 11; 5 
patients scored 10). Twelve patients who were classified as having NeP according to 
the NeuPSIG model, demonstrated hypoaesthesia to light touch (stroking with cotton 
wool) in their area of maximal pain. However in the LANSS, only allodynia is scored 
as a relevant sensory abnormality in response to light touch. If hypoaesthesia was 
scored as a relevant sensory abnormality for NeP, all these patients would have been 
identified as having NeP. In this case, the percentage of agreement would increase to 
76.3% and LANSS sensitivity would increase to 48% and specificity would reduce to 
77%. The frequency of positive pain descriptors and their discriminative function to 
identify NeP are documented in Table 5. The verbal descriptor of tingling sensation (p 
= 0.001) and the physical examination items of the presence of allodynia (p = 0.019) 
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and altered pin-prick sensation (p < 0.001) were statistically significant 
discriminators. Three item descriptors of LANSS (skin discoloration as symptom of 
possible autonomic nervous system dysfunction, tingling sensation and testing of 
allodynia) yield the highest score (score = 5) that is obtainable for a single question in 
LANSS. Less than 16% of patients with clinically classified NeP reported symptoms 
of possible autonomic nervous system dysfunction and allodynia. 
 
3.5.2 PD-Q and clinical classification of NeP 
The PD-Q identified 70 patients with a NeP component (mean score 23.2, SD ± 3.7) 
and 82 cases with no NeP component (mean score 11.7, SD ± 4.4) (Table 3). There 
was agreement between the PD-Q and the clinical classification in 95 cases (no NeP: 
n = 66, NeP: n = 29; Kappa 0.23, 95% CI .07 to .37) (Table 3), yielding 62.5% 
agreement with a sensitivity of 64% and a specificity of 62% (Table 4). Out of the 
remaining 57 cases, a larger number of patients (n = 41) were classified as having 
NeP with PD-Q compared to the clinical classification, which indicated no NeP. Most 
of these patients scored highly (≥ 4) on the verbal descriptors for the presence of 
burning pain, tingling sensation, numbness and sudden pain. The ROC curve is 
demonstrated in Figure 2. The AUC for the PD-Q was 0.63 (95% CI .53 to .73) and 
the appropriate cut-off score for our population was 18.5. The item descriptors of pain 
pattern (p = 0.035), tingling sensation (p = 0.001), sudden pain attacks/electric shocks 
(p = 0.001) and numbness (p = 0.023) were statistically significant discriminators for 






3.5.3. Agreement between questionnaires in identifying NeP 
There was agreement between LANSS and PD-Q in identifying NeP in 95 of the 152 
cases (no NeP: n = 77, NeP: n = 18; Kappa 0.21, 95% CI .09 to .33) (Table 3), 
yielding a 62.5% agreement between questionnaire outcomes. For the discordant 57 
cases, a NeP component was demonstrated in only five patients for LANSS, but in 52 
patients for PD-Q. Questions in the LANSS refer to how the patient’s pain felt over 
the last week. Seven patients did not experience much pain in the week prior to the 
assessment, but answered the PD-Q questions in relation to how their pain had felt in 
the past 4 weeks. This resulted in the PD-Q score indicating NeP.  
 
The PD-Q and LANSS have a number of questions in common. These include the 
presence of a tingling/prickling sensation and burning sensation, if light touch is 
painful in the area of pain and if pain can come on suddenly (Table 5). However, 
when comparing responses to the common questions from the two survey tools, 20 
patients answered the questions affirmatively in the PD-Q, resulting in the 
classification of NeP, but responded in the negative in the LANSS. The main 
discrepancies related to the presence/absence of burning pain (n = 13), sensitivity to 
light touch (n = 12) and sudden pain (n = 9). In the remaining 25 discordant cases and 
in five cases scoring positive on the LANSS but negative on PD-Q, discrepancies 
were found in responses to the above named descriptors in 15 patients. However, had 
patients answered these questions in PD-Q as answered in LANSS, the final score of 
PD-Q (NeP or no NeP) would not have changed. In 15 patients all questions were 
answered equally in both questionnaires, but due to scoring differences the overall 




3.6. Agreement between clinical classification and questionnaires where patients 
were classified as having NeP, no NeP or where the classification is unclear 
 
3.6.1. LANSS and clinical classification of NeP 
There was agreement between the LANSS and the clinical classification in 38 cases 
(no NeP: n = 14, unclear: n = 1, NeP: n = 23; Kappa 0.04, 95% CI -.01 to .09), which 
yielded a 25.0 % agreement. 
 
3.6.2. PD-Q and clinical classification of NeP 
There was agreement between the PD-Q and the clinical classification in 77 cases (no 
NeP: n = 11, unclear: n = 8, NeP: n = 58; Kappa 0.17, 95% CI .06 to .28), which 
yielded a 50.7 % agreement.  
 
3.6.3. Agreement between questionnaires in identifying NeP 
There was agreement between LANSS and painDETECT in identifying NeP in 67 
cases (no NeP: n = 40, unclear: n = 9, NeP: n = 18; Kappa 0.19, 95% CI 0.09 to .29), 





The NeuPSIG’s proposed diagnostic grading system [64] was feasible for clinical 
application in this cohort of neck/arm pain patients with a suspected nerve lesion. 
LANSS [9] and PD-Q [30] failed to identify a large number of patients with 
clinically-classified definite and probable NeP. The PD-Q demonstrated a higher 
sensitivity, but a lower specificity than LANSS. 
 
The NeuPSIG classification system has been recommended for use in primary care 
[35]. In the current study, the majority of patients were referred by their general 
practitioner and were therefore representative of a primary care population. The 
clinical assessment and classification of our cohort necessitated considerable time and 
specific clinical expertise. Considering an average general practice consultation time 
of 15 minutes [14;19], health professionals working in primary care may not have 
time for an appropriate in-depth clinical assessment or have the requisite knowledge 
and skills to apply this grading system. 
 
In our study, 82 patients (54%) reported the neck/trapezius/scapula/shoulder area as 
their main area of pain. These body regions correlate with specific cervical nerve root 
pain distributions [63], but are also a common area for musculoskeletal pain and 
referred somatic pain [23]. Mixed nociceptive and NeP mechanisms, which were 
likely to co-exist in our patient sample, have been acknowledged by numerous authors 
[2;3;30;49;64]. In the context of predominant pain mechanisms, the value of sensory 
pain descriptors has been previously raised [4;16]. The combination of some items 
can discriminate between non-NeP and NeP groups [9;11;17;27;44], however their 
relevance and incorporation into the NeuPSIG grading system is debatable 
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[6;37;48;64]. In our study, the most dominant volunteered discriminators between the 
no NeP group and all others were the sensory descriptors electric shock, followed by 
tingling, sharp and spontaneous pain and numbness, corresponding with discriminant 
descriptors of PD-Q and LANSS, and hot and shooting. Unlike other studies 
[9;11;17;27;44], pain descriptors were volunteered, not chosen from a nominated 
descriptors list, thus lending credence to their presence. The descriptor ache, 
commonly associated with nociceptive pain [8;28;49;52;61], was reported in our 
patients with NeP components, consistent with other studies [26;61;67]. 
 
For the diagnosis of NeP, sensory abnormalities have to be present “concordant with 
the distribution of pain”  (Criterion 3) [64]. This wording may however be open to 
different interpretations and this could influence patient classification. ‘Concordant’ 
can be defined as: “being in agreement with” [21], allowing for interpretations 
including “sensory abnormalities have to spatially overlap the area of pain” or 
“sensory abnormalities are associated with the pain distribution and innervation 
territory of the affected nervous structure, but they do not necessarily overlap the pain 
area”. For example, distal dermatomal hypoaesthesia, (as seen in radiculopathy), 
could indicate a lesion of the somatosensory system, but its presence does not 
necessarily indicate the presence of NeP in an associated proximal main pain area.  
 
The sensitivity of LANSS and PD-Q was much lower compared to previously 
reported studies [9;30], and the diagnostic accuracy of both questionnaires diminished 
further with the classification of patients with NeP (probable and definite NeP 
combined), non-NeP and unclear cases. These discrepancies to previous reports may 
partly be explained by the differences in clinical characteristics of respective study 
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cohorts, and this assumption is supported by the fact that only few of the item 
descriptors of LANSS and PD-Q were discriminative for identifying NeP. Both 
questionnaires were validated in specific pain clinic populations with and without 
NeP, and patients with mixed pain were excluded [9;30]. Such study design can 
introduce spectrum bias and lead to exaggeration of both sensitivity and specificity 
[55]. In contrast, our cohort consisted of mixed pain aetiologies (e.g. spinal 
degenerative conditions, radiculopathy, musculoskeletal). 
 
The presence of mixed pain presentations seems to influence the discriminative ability 
of LANSS. Whilst LANSS demonstrated high sensitivity (70% - 89%) and specificity 
(94.2% - 96.6%) in patient groups resembling the cohorts in the validation study [65; 
68], sensitivity reduced slightly from 85.9% to 81.8% with the inclusion of mixed 
pain presentations in a cohort of 156 patients (42.9% NeP, 14% mixed pain) [58]. In a 
large sample of patients with cancer, which was labelled as having a mixed pain 
mechanism [5;51], sensitivity was 29.5% [51], similar to our data. The LANSS may 
be most sensitive in patient cohorts who demonstrate mainly positive sensory gains 
rather than negative sensory signs. Specifically, only 11% of our definite NeP patients 
demonstrated allodynia, and a positive response regarding autonomic dysfunction was 
reported in only 15.6% of patients compared to 90% and 55% respectively in the 
LANSS validation study [9]. Similar observations to ours have been reported in 
patients with low back-related leg pain [61]. In the original LANSS studies [9], a 
significant association between allodynia and hyperalgesia was found, however in our 
cohort, hyposensitivity seemed to be more frequent than hypersensitivity, consistent 
with findings from previous studies [57;61]. The specificity of LANSS was 
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comparable to previous studies [9;51;58;65;68], indicating its usefulness in negating 
NeP components in patients with chronic musculoskeletal pain. 
 
The PD-Q demonstrated a sensitivity of 64% in identifying NeP, which is similar to 
the sensitivity (67%) reported in a Spanish patient cohort of 221 patients with NeP 
(32%), nociceptive (32%) and mixed pain (36%) [24]. However, our calculated 
sensitivity might not truly reflect the identification of NeP: as a self-administered tool, 
the PD-Q is open to individual interpretation. Eight of our patients failed to identify 
their main area of pain on the PD-Q body chart and 45 patients indicated additional, 
multiple pain areas (78% related to LBP and leg pain). Thus, it is possible that in 35% 
of our patient cohort, the responses given in PD-Q might have related to areas 
additional to the main pain area. Out of these 53 patients, 36 were clinically classified 
as definite and probable NeP patients and PD-Q identified 24 of these patients. Our 
findings support the statement that the discriminative ability of NeP screening tools is 
only reliable when applied to one specific painful area [16;53]. Out of 29 patients 
classified by PD-Q and the clinical assessment as having NeP, there were inconsistent 
responses to the common questions between LANSS and PD-Q in 25% of cases. If 
responses to these questions had been similar in the PD-Q as in LANSS, the 
sensitivity of PD-Q would have reduced to 48.9%. Providing specific instructions on 
how to complete the PD-Q therefore appears important. 
 
With a lack of published studies documenting clinical diagnostic accuracy and 
reliability of the English version of PD-Q in patients with peripheral NeP [1;16], the 
validity of PD-Q for use in screening patients with neck/arm pain may be 
questionable. It is unclear if the lowered sensitivity of PD-Q in our study might relate 
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to variations in patient cohorts, as specific patient characteristics were not reported in 
the original validation study [30]. 
 
Fundamental differences also exist between LANSS and PD-Q design, i.e. the 
timeframe of the presenting pain, the number and type of items included, the phrasing 
of the questions and the scoring method. Whilst LANSS uses fixed scores for each 
question, sensory descriptor items are weighted in PD-Q, thus responses could be 
vulnerable to psychological factors such as hypervigilance and catastrophizing, as 
demonstrated in another study [40], potentially contributing to an overall higher score.  
 
The differences in design of LANSS and PD-Q tools, together with the low level of 
agreement between instruments, would not support the interchangeable use of these 
questionnaires. Furthermore, the discriminative ability of these tools in identifying 
NeP components in patients with neck/upper limb pain of mixed aetiology is 
questionable. Our findings strongly support the notion that results of NeP screening 
tools should always be used in conjunction with comprehensive clinical assessment of 
the patient and should not replace clinical judgement [22;34;37].  
 
Our study findings should be interpreted in light of various limitations. As patients 
were suspected of having a nerve lesion, there may be an element of selection bias 
against patients with no nerve lesion, although the presence of a nerve lesion does not 
necessarily equate with NeP. While sensory testing of thermal sensibility was not 
performed in this study, consistent with previous methodology [39;66], this might 
have increased the number of patients demonstrating sensory alterations and probable 
or definite NeP. Blinding of the investigator and an assessment by a second clinician 
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would have enhanced the validity of our findings, however this was not possible for 
reasons previously outlined in our methods. These issues reflect the real world where 
tensions between what might be robust pure research collide with pragmatic design. 
While investigation of the reliability of the NeuPSIG grading system was not the 
primary aim of our study, this should be addressed in a future study. 
 
The NeuPSIG’s proposed grading system for NeP could readily be applied to a cohort 
of patients with neck/upper limb pain. This classification approach might not be 
feasible in primary care settings for patients with complex pain presentations due to 
the time and specific expertise required for classification. The diagnostic accuracy of 
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Table 1  
Characteristics of patients (N = 152) with neck/upper limb pain classified according to the NeuPSIG grading system as no,  
possible, probable or definite neuropathic pain (NeP). 
 No NeP Possible NeP Probable NeP Definite NeP 
N 15 27 65 45 
Age (years)a 58.0 (14.4) 51.2 (10.0) 51.1 (12.0) 52.6 (11.0) 
Gender (women/men) 5/10 14/13 33/32 20/25 
Symptoms duration (months)b 18.0  
(3.0 – 240.0) 
9.0  
(2.0 – 126.0) 
17.0  
(1.5 – 228.0) 
10.0  
(1.0 – 204.0) 
Pain now (NRS 0 – 10)a 3.6 (2.4) 4.5 (2.3) 4.8 (2.3) 
(n = 64) 
4.7 (2.2) 
Maximal pain intensity during last 4 weeks  
(NRS 0 – 10)a  
6.7 (2.6) 7.1 (2.5) 7.5 (2.3) 
(n = 63) 
7.8 (1.9) 
Average pain intensity during last 4 weeks  
(NRS 0 - 10)a  
5.1 (2.8) 6.0 (2.4) 5.9 (2.0) 
(n = 63) 
6.0 (1.9) 
N on antidepressants, anticonvulsants or opioids 2 (13.3 %) 6c (22.2 %) 21d (32.3 %) 16e (35.5 %) 
N on analgesics (paracetamol, NSAIDS) 2 (13.3 %) 8 (29.6 %) 15 (23.1 %) 17 (37.8%) 




Pain diagnoses/pain presentationsa and neuropathic pain (NeP) classifications in patients (N = 152) with neck/upper limb pain. 
  Clinical classification LANSS painDETECT 


















N 152 15 27 65 45 129 23 46 36 70 
Radiculopathy           
Cervical radiculopathyb 33   9 24 24 9 7 7 19 
Sensory cervical radiculopathyc 12  1 4 7 10 2 3 4 5 
Motor radiculopathyd 5   4 1 5  2 3  
Radicular pain           
Radicular neck/arm pain with distal 
paraesthesia in dermatomal distribution 
19  4 11 4 16 3 2 5 12 
Radicular neck/arm pain 11  1 7 3 10 1 3 4 4 
Radicular neck/arm pain with non dermatomal 
distal paraesthesia 
8  2 5 1 6 2 1 2 5 
Radicular pain with bilateral hand paraesthesia  3   2 1 3   1 2 
Neck pain 13 5 4 3 1 13  7 3 3 




Neck pain with bilateral arm and/or hand pain 
/paraesthesia 
14 4 3 7  13 1 7 1 6 
Whiplash injury related pain 6  4 2  4 2 1 2 3 
Cervical myelopathy 2    2 2  1  1 
Carpal tunnel syndrome 2   2  2  1  1 
Other 6 1 2 2 1 4 2 2 2 2 
a As determined by clinician based on history, examination results (neurological and musculoskeletal status) and results of investigations. 
b Dermatomal pain/symptom distribution plus sensory dermatomal deficit plus motor impairment (either reflex absent/diminished or myotomal 
weakness). 
c Dermatomal pain/symptom distribution plus sensory dermatomal deficit, no motor impairment. 
d Dermatomal pain/symptom distribution plus motor impairment, no sensory dermatomal deficit. 
 
Table 3  
Frequencies of neuropathic pain (NeP) in patients (N = 152) with neck/upper limb 
pain, using two classification categories: no NeP – NeP. 
  Clinical classification  
  No NeP NeP Total 
LANSSa No NeP 94 35 129 
NeP 13 10 23 
 Total 107 45 152 
    
  Clinical classification  
  No NeP NeP Total 
painDETECTb No NeP 66 16 82 
 NeP 41 29 70 
 Total 107 45 152 
    
  painDETECT  
  No NeP NeP Total 
LANSSc No NeP 77 52 129 
 NeP 5 18 23 
 Total 82 70 152 
a 68.4 % of agreement between clinical classification and LANSS. 
b 62.5 % of agreement between clinical classification and painDETECT. 




Accuracy of screening tools in identifying patients with neuropathic pain 
 % Sensitivity % Specificity PPV NPV LR+ LR- DOR 
LANSS 22 88 0.44 0.31 1.83 0.89 2.0 
painDETECT 64 62 0.42 0.80 1.68 0.58 2.9 
LANSS: Leeds Assessment of Neuropathic Symptoms and Signs pain scale; PPV: Positive predictive value; NPV: Negative predictive value; 




Frequency of pain descriptors with logistic regression analysis for each item descriptor 
 
Questionnaire Item descriptor NeP 
(n = 45) 
 No NeP 
(n = 107) 
  
  Yes (n) %  Yes (n) %  p-value 
LANSS Pricking/tingling/pins and needles  36 80  57 53.3  0.001 
 Skin discoloration 7 15.6  7 6.5  0.092 
 Sensitivity to light touch  7 15.6  21 19.6  0.549 
 Sudden bursts of pain/electric shocks 24 53.3  44 41.1  0.168 
 Feeling of altered skin temperature/hot/burning 26 57.8  46 43  0.095 
 Allodynia to light touch 5 11.1  2 1.9  0.019 
 Altered pin-prick sensation 36 80  42 39.3  <0.001 
         
PD-Q Pain Pattern       0.035 
 Persistent pain with slight fluctuation 10 22.2  36 33.6   
 Persistent pain with pain attacks 23 51.1  32 29.9   
 Pain attacks without pain between them 4 8.9  17 15.9   
 Pain attacks with pain between them 11 24.4  29 27.1   
 
 42 
 Radiating pain 36 80  77 72  0.845 
 Burning sensation 26 57.8  54 50.5  0.510 
 Tingling/prickling sensation 37 82.2  59 55.1  0.001 
 Painful light touch 5 11.1  21 19.6  0.198 
 Sudden pain attacks/electric shocks 36 80  56 52.3  0.001 
 Cold or heat painful 7 15.6  20 18.7  0.682 
 Numbness 33 73.3  57 53.3  0.023 
 Slight pressure painful 28 62.2  53 49.5  0.150 












































































Fig. 1 Frequency of sensory descriptors volunteered by 152 patients with neck/upper limb pain,  




Fig. 2 ROC curve and AUC of the Leeds Assessment of Neuropathic Symptoms and 
Signs (LANSS) and painDETECT questionnaire (PD-Q)  
 
 
